Cardiovascular Systems, Inc. (CSI) (Nasdaq:CSII) announced today that it has filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC). The shelf registration statement will permit the company to sell up to $75 million of equity or debt securities, providing greater flexibility to take advantage of financing opportunities as needed. As of the date of this release, CSI has no specific plans to offer, and is not required to offer, the securities covered by the registration statement. The terms of any offering under the registration statement will be established at the time of the offering and will be described in a prospectus supplement filed with the SEC. Unless otherwise indicated, the proceeds from the sale of any securities will be used for general corporate purposes including, but not limited to, sales and marketing expansion, working capital, continuing research and development, acquisitions and debt repayment. Once declared effective by the SEC, the registration statement would remain in place for a period of three years. A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release is not an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s Stealth 360°™, Diamondback 360 ® and Diamondback Predator 360 ® Orbital PAD Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback 360° in August 2007 and for the Stealth 360° in March 2011. To date, more than 46,000 PAD procedures have been performed using the Diamondback 360° in leading institutions across the United States. CSI has also commenced its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its Diamondback 360° System in treating coronary arteries. The coronary system is under clinical investigation and is currently not commercially available in the United States.
For more information, visit the company’s website at www.csi360.com.